ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand

The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab significantly reduces low-density lipoprotein cholesterol (LDL-C). This study (ODYSSEY EAST) assessed the efficacy and safety of alirocumab vs ezetimibe in high cardiovascular risk patients from Asia. Patients (n = 615) from Chin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical lipidology 2020-01, Vol.14 (1), p.98-108.e8
Hauptverfasser:	Han, Yaling, Chen, Jiyan, Chopra, Vijay Kumar, Zhang, Shuyang, Su, Guohai, Ma, Changsheng, Huang, Zhouqing, Ma, Yingyan, Yao, Zhuhua, Yuan, Zuyi, Zhao, Qiang, Kuanprasert, Srun, Baccara-Dinet, Marie T., Manvelian, Garen, Li, Jianyong, Chen, Rui
Format:	Artikel
Sprache:	eng
Schlagworte:	Alirocumab Hypercholesterolemia LDL-C Lipid-lowering therapy PCSK9
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!